1st Pitch Life Science- Philadelphia: “Eavesdropping on Investors’ Closed Door Discussions”
“
“Eavesdropping on investors‘ closed door discussions” gives entrepreneurs the inside track on what happens after a start-up company presents to investors. Typically, after a start up company’s team leaves the room investors have a private discussion about whether the opportunity merits further investigation and possible investment. 1st Pitch Life Science-Philadelphia offers local company presenters and audience participants the chance to listen in on these closed door discussions to learn what really matters to investors. This event offers excellent networking opportunities for investors, university technology transfer professionals, entrepreneurs, and business professionals in the Philadelphia entrepreneurial ecosystem. It provides a supportive learning environment for entrepreneurs.
“
For more information about Mid-Atlantic BioAngels and to make a submission for evaluation of your startup please visit their
website: http://bioangels.net/.
Mid-Atlantic Bioangels was formed in 2013 to provide an unmet need in the Mid-Atlantic region for early-stage life-science entrepreneurship, providing early life science entrepreneurs a venue to present their companies, obtain funding and provide mentoring, feedback, networking, and information for corporate development. A great article by Kira M. Newman can be found here
http://tech.co/mid-atlantic-bio-angels-life-sciences-investors-2013-06
More information on the !st Pitch Life Sciences meetings can be found at www.1stpitchlifescienc.com. Further information can be obtained at nfo@1stpitchlifescience.com.For sponsorship questions please email Bernie@bioangels.net.
Meeting Coverage
Three companies are to be presented
Hastke Inc is a device company with a best-in-class, real-time 3D visualization technology that can de-risk the drug development process for pharma. In the future, their technology has the potential to become an important diagnostic tool for physicians.
LytPhage is a new biotech company using novel bioengineering to develop therapeutics to address the worldwide crisis of antibiotic resistant organisms. They are developing a treatment for vancomycin resistant systemic infections with their platform, which can be adapted for other problematic organisms.
RAbD Biotech uses proprietary computational methods to design biologic agents capable of treating severe diseases. RAbD’s lead product candidate is a potential first-in-class treatment for ovarian cancer, a disease characterized by late detection, few therapeutic options, and high mortality.
The meeting format includes:
- 15-20 minute meeting presentation
- group discussion/questions
- panel opinions (panel of experienced venture capitalists)
Notes from the meeting will be put in future postings.
Please also see Twitter handles for meeting coverage using the following hashtags and handles
hashtags handles
#MABA #lifescience #PHL #biotech #startup @BioAngelsGroup @pharma_BI @RAbDBiotech
#VC #venturecapital # bioangels #entrepreneur
#angelinvestor
The meeting had a live voting on Surveymonkey for each presentation using your smartphone. The address for the voting was
www.1stpitchlifescience.com/vote
where event participants vote on each individual presentation and a “Best in Show”.
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.